T. Rowe Price Investment Management, Inc. Cytokinetics Inc Transaction History
T. Rowe Price Investment Management, Inc.
- $158 Billion
- Q2 2025
A detailed history of T. Rowe Price Investment Management, Inc. transactions in Cytokinetics Inc stock. As of the latest transaction made, T. Rowe Price Investment Management, Inc. holds 17,602,440 shares of CYTK stock, worth $1.1 Billion. This represents 0.37% of its overall portfolio holdings.
Number of Shares
17,602,440
Previous 9,955,251
76.82%
Holding current value
$1.1 Billion
Previous $400 Million
45.36%
% of portfolio
0.37%
Previous 0.26%
Shares
11 transactions
Others Institutions Holding CYTK
# of Institutions
384Shares Held
129MCall Options Held
3.62MPut Options Held
1.14M-
Black Rock Inc. New York, NY14.7MShares$913 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA12MShares$746 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA7.83MShares$487 Million0.05% of portfolio
-
State Street Corp Boston, MA6.37MShares$397 Million0.01% of portfolio
-
Deep Track Capital, LP Greenwich, CT3.65MShares$227 Million4.28% of portfolio
About CYTOKINETICS INC
- Ticker CYTK
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 94,144,096
- Market Cap $5.86B
- Description
- Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates i...